Visceral Adiposity and Progression of ADPKD: A Cohort Study of Patients From the TEMPO 3:4 Trial.
Kristen L NowakFederica MorettiNicole BussolaCortney N SteeleAdriana V GregoryTimothy L KlineSumana RamanathanGiovanni TraplettiCesare FurlanelloLinda McCormickMichel ChoncholPublished in: American journal of kidney diseases : the official journal of the National Kidney Foundation (2024)
We analyzed images from a previous study with the drug tolvaptan conducted in patients with autosomal dominant polycystic kidney disease (ADPKD) to measure the amount of fat tissue surrounding the kidneys (visceral fat). We had previously shown body mass index can predict kidney growth in this population; now we determined whether visceral fat was an important factor associated with kidney growth. Using a machine learning tool to automate measurement of fat in images, we observed that visceral fat was independently associated with kidney growth, that it was a better predictor of faster kidney growth in lean patients than body mass index, and that having more visceral fat made treatment of ADPKD with tolvaptan less effective.
Keyphrases
- polycystic kidney disease
- adipose tissue
- insulin resistance
- machine learning
- body mass index
- fatty acid
- end stage renal disease
- randomized controlled trial
- clinical trial
- chronic kidney disease
- ejection fraction
- heart failure
- type diabetes
- convolutional neural network
- emergency department
- prognostic factors
- skeletal muscle
- peritoneal dialysis
- open label
- body composition
- phase iii
- big data
- phase ii
- acute heart failure
- electronic health record
- replacement therapy